Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) on Tuesday shared data from cohort 4 of the Phase 1 trial evaluating soquelitinib in patients with moderate-to-severe atopic dermatitis.

WESTERVILLE, Ohio--(BUSINESS WIRE)--The Marzetti Company (Nasdaq: MZTI) announced today that it will release its second quarter fiscal year 2026 financial results prior to the opening of the market on Tuesday, February 3, 2026. The company will also host a conference call that same day beginning at 10:00 am ET to review its financial results. The conference call will be webcast live via the Internet. To listen to the webcast, go to the company's website, investors.marzetticompany.com, click on.

On Jan. 13, the U.S. Bureau of Labor Statistics released December's Consumer Price Index data, showing that headline inflation rose at a year-over-year (YOY) pace of 2.7%.

Why I Am Bullish On Gaming, But Bearish On Roblox

USAR gains an edge over NioCorp as progress at its Stillwater magnet facility and strong funding support a path toward U.S. commercial production.

USB tops Q4 earnings estimates as net interest income and fee income rise year over year, aided by lower expenses and improved operating efficiency.

Oil markets are moving higher despite trade war worries.

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Klarna Group PLC (“Klarna” or the “Company”) (NYSE: KLAR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BigBear.ai Holdings, Inc. (“BigBear” or the “Company”) (NYSE: BBAI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

GE is heading into Q4 earnings with double-digit revenue growth expected, driven by strong engine demand, services strength and defense momentum.

With increased volatility could come an opportunity to pick up a steady dividend stock at a slightly lower price and perhaps a few more basis points of yield.

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Fermi Inc. (“Fermi” or the “Company”) (NASDAQ: FRMI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The Global X Uranium exchange-traded fund is still simmering after its massive advance for much of last year.

Coca-Cola chairman and CEO James Quincey told CNBC at the World Economic Forum in Davos that the U.S. consumer "continues to be robust."

RIVERSIDE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Provident Financial Holdings, Inc. (“Company”) (Nasdaq GS: PROV), the holding company for Provident Savings Bank, F.S.B.

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against agilon health, inc. (“Agilon” or the “Company”) (NYSE: AGL).

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed on behalf of shareholders of Quantum Biopharma Ltd. (“Quantum” or the “Company”) (NASDAQ: QNTM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of America's Car-Mart, Inc. (NASDAQ: CRMT) resulting from allegations that America's Car-Mart may have issued materially misleading business information to the investing public.

Award Brings Columbus Network to 304 Miles NEW YORK, Jan. 20, 2026 /PRNewswire/ -- Lightpath today announced it has secured a third major network award in the Greater Columbus market, reflecting continued, success-based investment driven by hyperscale demand for AI-ready connectivity infrastructure. The latest award builds directly on a network currently under construction, adding 55 route miles of 100% underground, multi-conduit network extending southwest of Columbus toward Cincinnati.

ORIC Pharmaceuticals is advancing two best-in-class small molecule inhibitors targeting resistance mechanisms in prostate and lung cancer. ORIC's $413 million cash position, bolstered by a 2025 equity raise, secures operations and Phase 3 trial funding into the second half of 2028. Rinzimetostat and enozertinib have shown promising efficacy and safety in early trials, with both candidates entering registrational Phase 3 studies by 2026.